Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amneal Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports First Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2024 Results on May 3, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Move to Nasdaq
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Third Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Third Quarter 2023 Results on November 7, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives First Product Approval in China
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2024 Diversified Communications. All rights reserved.